Literature DB >> 33505518

Rivaroxaban: Expanded Role in Cardiovascular Disease Management-A Literature Review.

Muhammad Ajmal1, Jacob Friedman1, Qurat Ul Ain Riaz Sipra1, Tom Lassar1.   

Abstract

Direct oral anticoagulants (DOACs) are widely used for the prevention of stroke in nonvalvular atrial fibrillation, treatment of deep venous thrombosis and pulmonary embolism, and as prophylaxis after hip and knee surgery after approval by the Food and Drug Administration. In the last decade, DOACs were studied for various indications; this review is focused on rivaroxaban, a factor Xa inhibitor, which is used in an expanded evidence-based fashion for coronary artery disease, peripheral artery disease, heart failure, malignancy, and prophylaxis of deep venous thrombosis in acute medical illnesses.
Copyright © 2021 Muhammad Ajmal et al.

Entities:  

Year:  2021        PMID： 33505518      PMCID： PMC7810545          DOI： 10.1155/2021/8886210

Source DB:  PubMed          Journal:  Cardiovasc Ther        ISSN： 1755-5914            Impact factor:   3.023


  80 in total

1.  Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists.

Authors:  E S Eerenberg; S Middeldorp; M Levi; A W Lensing; H R Büller
Journal:  J Thromb Haemost       Date:  2015-08-22       Impact factor: 5.824

2.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

Review 3.  Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis.

Authors:  Maria Cristina Vedovati; Federico Germini; Giancarlo Agnelli; Cecilia Becattini
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

4.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Cost effectiveness analysis of direct oral anticoagulant (DOAC) versus dalteparin for the treatment of cancer associated thrombosis (CAT) in the United States.

Authors:  Ang Li; Poorni M Manohar; David A Garcia; Gary H Lyman; Lotte M Steuten
Journal:  Thromb Res       Date:  2019-05-16       Impact factor: 3.944

6.  Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum.

Authors:  Adam Cuker; Allison Burnett; Darren Triller; Mark Crowther; Jack Ansell; Elizabeth M Van Cott; Diane Wirth; Scott Kaatz
Journal:  Am J Hematol       Date:  2019-04-16       Impact factor: 10.047

7.  Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin.

Authors:  Joji Hagii; Hirofumi Tomita; Norifumi Metoki; Shin Saito; Hiroshi Shiroto; Hiroyasu Hitomi; Takaatsu Kamada; Satoshi Seino; Koki Takahashi; Yoshiko Baba; Satoko Sasaki; Takamitsu Uchizawa; Manabu Iwata; Shigeo Matsumoto; Tomohiro Osanai; Minoru Yasujima; Ken Okumura
Journal:  Stroke       Date:  2014-07-31       Impact factor: 7.914

8.  Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.

Authors:  Austin A Robinson; Cory R Trankle; Grayson Eubanks; Christopher Schumann; Paul Thompson; Ryan L Wallace; Shouri Gottiparthi; Benjamin Ruth; Christopher M Kramer; Michael Salerno; Kenneth C Bilchick; Cody Deen; Michael C Kontos; John Dent
Journal:  JAMA Cardiol       Date:  2020-06-01       Impact factor: 14.676

9.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).

Authors:  Annie M Young; Andrea Marshall; Jenny Thirlwall; Oliver Chapman; Anand Lokare; Catherine Hill; Danielle Hale; Janet A Dunn; Gary H Lyman; Charles Hutchinson; Peter MacCallum; Ajay Kakkar; F D Richard Hobbs; Stavros Petrou; Jeremy Dale; Christopher J Poole; Anthony Maraveyas; Mark Levine
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

Review 10.  New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis.

Authors:  Jonas Oldgren; Lars Wallentin; John H Alexander; Stefan James; Birgitta Jönelid; Gabriel Steg; Johan Sundström
Journal:  Eur Heart J       Date:  2013-03-06       Impact factor: 29.983
View more
  3 in total

1.  The Antithrombotic Effect of Recombinant Neorudin on Thrombi.

Authors:  Yu-Bin Liu; Lin Zhang; Xing-Chen Zhou; Ying Zhou; Yun Liu; Can Zheng; Xiao Xu; Pan-Pan Geng; Chun-Hua Hao; Zhuan-You Zhao; Chu-Tse Wu; Ji-De Jin
Journal:  Drug Des Devel Ther       Date:  2022-06-02       Impact factor: 4.319

2.  Evaluation of Herb-Drug Interaction Between Danshen and Rivaroxaban in Rat and Human Liver Microsomes.

Authors:  Xu Wang; Jingjing Fa; Yuanjin Zhang; Shengbo Huang; Jie Liu; Junqing Gao; Lina Xing; Zongjun Liu; Xin Wang
Journal:  Front Pharmacol       Date:  2022-07-19       Impact factor: 5.988

3.  Analysis of the Preventive Action of Rivaroxaban against Lower Extremity Deep Venous Thrombosis in Patients after Laparoscopic Radical Gastrectomy.

Authors:  Qinhui Dong; Xiayin Zhu; Yafen Gao; Zhengrong Wang; Dexing Zheng; Jian Zhu
Journal:  Comput Math Methods Med       Date:  2022-09-10       Impact factor: 2.809
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.